Hostname: page-component-7c8c6479df-nwzlb Total loading time: 0 Render date: 2024-03-28T16:19:36.413Z Has data issue: false hasContentIssue false

Further Observations on the Duration of Depot Neuroleptic Maintenance Therapy in Schizophrenia

Published online by Cambridge University Press:  29 January 2018

D. A. W. Johnson*
Affiliation:
University Hospital of South Manchester, West Didsbury, Manchester, 20

Summary

Two patient samples, with different criteria for selection, have been surveyed following maintenance therapy discontinuation. The patients had previously remained in a steady mental state on depot injections for periods varying between one and four years. Both the rates of relapse and pattern of relapse suggest that patients responding to medication need to remain on maintenance therapy for a minimum of four years. The results further suggest that in chronic schizophrenia the drugs only suppress symptoms and that the prognosis following discontinuation is substantially unchanged by increased duration of medication, even after four years. The possibility of using short-term ‘drug holidays’ to reduce the risk of unwanted effects was explored; after only three months without drugs, the risks of relapse were significantly increased.

Type
Research Article
Copyright
Copyright © Royal College of Psychiatrists, 1979 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Gibson, A. C. (1978) Depot injections and tardive dyskinesia. British Journal of Psychiatry, 132, 361–5.Google Scholar
Hirsch, S. R., Gaind, R., Rhode, P. D., Stevens, B. C. & Wing, J. K. (1973) Out-patient maintenance of chronic schizophrenic patients with long acting phenothiazine. British Medical Journal i, 633–7.Google Scholar
Hogarty, G. E., Goldberg, S. C., Schooler, N. R., Ulrich, R. F. and the Collaborative Study Group (1974) Drug and sociotherapy in the aftercare of schizophrenic patients. Archives of General Psychiatry, 31, 603–8.Google ScholarPubMed
Hogarty, G. E., Ulrich, R., Mussare, F. & Aristigueta, N. (1976) Drug discontinuation among long term successfully maintained schizophrenic out-patients. Diseases of the Nervous System, 57, 494500.Google Scholar
Johnson, D. A. W. (1976a) The expectation of outcome from maintenance therapy in chronic schizophrenic patients. British Journal of Psychiatry, 128, 246–50.CrossRefGoogle ScholarPubMed
Johnson, D. A. W. (1976b) The duration of maintenance therapy in chronic schizophrenia. Acta Psychiatrica Scandinavica, 53, 298301.Google Scholar
Johnson, D. A. W. (1977) Practical considerations in the use of depot neuroleptics for the treatment of schizophrenia. British Journal of Hospital Medicine, 17, 546–59.Google Scholar
Johnson, D. A. W. (1978) The prevalence and treatment of drug induced extrapyramidal symptoms. British Journal of Psychiatry, 132, 2730.Google Scholar
Johnson, D. A. W., Breen, M. (1979) Weight changes with depot neuroleptic maintenance therapy. Acta Psychiatrica Scandinavica, 59, 525–8.CrossRefGoogle ScholarPubMed
Johnson, D. A. W. (1979) Clinical considerations in the use of depot neuroleptics for the treatment of schizophrenia. In Management of Schizophrenia: Biological and Sociological Aspects (Ed. by van Praag, H. M.). Utrecht: Van Gorcum.Google Scholar
Leff, J. P. & Wing, J. K. (1971) Trial of maintenance therapy in schizophrenia. British Medical Journal, iii, 559604.Google Scholar
McClelland, H. A., Blessed, G., Bhate, S., Ali, N. & Clarke, P. A. (1974) The abrupt withdrawal of antiparkinson drugs in schizophrenic patients. British Journal of Psychiatry, 124, 151–9.Google Scholar
Mindham, R. H. S. (1976) Assessment of drug induced extrapyramidal reactions. British Journal of Clinical Pharmacology, Supplement 3, 395400.Google Scholar
Submit a response

eLetters

No eLetters have been published for this article.